Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FXYD5 encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. Additionally we are shipping FXYD5 Proteins (7) and FXYD5 Kits (2) and many more products for this protein.
Showing 10 out of 63 products:
Human Polyclonal FXYD5 Primary Antibody for ELISA, IHC - ABIN249469
Tsuiji, Takasaki, Sakamoto, Irimura, Hirohashi: Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. in Glycobiology 2003
Show all 2 Pubmed References
Human Polyclonal FXYD5 Primary Antibody for WB - ABIN2776197
Miller, Davis: FXYD5 modulates Na+ absorption and is increased in cystic fibrosis airway epithelia. in American journal of physiology. Lung cellular and molecular physiology 2008
the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase (show ATP1A1 Antibodies) acts as a positive or negative regulator of intercellular adhesion.
Knockdown of FXYD5 in MDA-MB-231 breast cancer cells largely decreases expression and secret (show IRF6 Antibodies)ion of the chemok (show CCL2 Antibodies)ine CCL2 (MCP-1). A related effect has also been observed in renal cell carcinoma cells.
Study demonstrated that the expression of FXYD1 (show FXYD1 Antibodies), FXYD3 (show FXYD3 Antibodies) and FXYD5 is elevated in the lungs of Acute respiratory distress syndrome patients
Dysadherin-silenced side population cells exhibited reduced expression of Bcl-2 (show BCL2 Antibodies) and Bax (show BAX Antibodies) compared with that prior to silencing.
we are focusing on the role of dysadherin in E-cadherin (show CDH1 Antibodies) downregulation, the various expression patterns of the molecule in head and neck cancer
Findings suggest that dysadherin might contribute to breast cancer progression through AKT (show AKT1 Antibodies) activation.
These results suggest a role of let-7a down-regulation in the development of thyroid neoplasias of the follicular histotype, likely regulating dysadherin protein expression levels.
Data show that osteoblasts are the major cell type of the bone marrow that affect RCC (show XRCC1 Antibodies) cells by secreting factors that increase the expression of dysadherin and CCL2 (show CCL2 Antibodies) in the tumor cells leading to enhanced cell migration.
This is the first report on expression of dysadherin in the male gonad and in spermatozoa.
Overexpression of Snail (show SNAI1 Antibodies), Slug (show SNAI2 Antibodies), and dysadherin and activation of Wnt (show WNT2 Antibodies) and PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) signaling was associated with inactivated E-cadherin (show CDH1 Antibodies) in the spindle cells of monophasic fibrous synovial sarcomas.
FXYD5 mediates metastatic progression through regulation of the beta Na(+)-K(+)-ATPase (show ATP1A1 Antibodies) subunit in the 4T1 mouse breast cancer model.
transfection of M1 epithelial cell line with FXYD5 largely increases lipopolysaccharide (LPS (show TLR4 Antibodies)) stimulated CCL2 (show CCL2 Antibodies) mRNA and secretion of the translated protein
FXYD5 affects cell polarization through its interaction with Na(+)-K(+)-ATPase (show ATP1A1 Antibodies).
Expressing FXYD5 in mouse kidney collecting duct cell line M1 led to a large decrease in amiloride-insensitive transepithelial electrical resistance as well as increased permeability to 4-kDa dextran.
The role of FXYD5 in Na,K-ATPase (show ATP1A1 Antibodies) activity, its cellular and tissue distribution, and its biochemical properties are reported.
data suggest that different FXYD proteins interact similarly with the Na(+)-K(+)-ATPase (show ATP1A1 Antibodies) and their transmembrane domains
FXYD5 is significantly increased in the lungs and nasal epithelium of cystic fibrosis (show S100A8 Antibodies) mice as assessed by RT-PCR.
This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants.
FXYD domain-containing ion transport regulator 5
, FXYD domain containing ion transport regulator 5
, keratinocytes associated transmembrane protein 1
, ion channel homolog RIC
, oncoprotein induced transcript 2
, oncoprotein-induced protein 2